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Abstract
Background Broncho-pleural fistula (BPF) and respiratory failure (RF) are life-threatening complications after lung cancer 
surgery and can result in long-term hospitalization and decreased quality of life. Risk assessments for BPF and RF in addi-
tion to mortality and major morbidities are indispensable in surgical decision-making and perioperative care.
Methods The characteristics and operative data of 80,095 patients who had undergone lung cancer surgery were derived 
from the 2014 and 2015 National Clinical Database (NCD) of Japan datasets. After excluding 1501 patients, risk models 
were developed from these data and validated by another dataset for 42,352 patients derived from the 2016 NCD dataset. 
Receiver operating characteristic curves were generated for postoperative BPF and RF development. The concordance-index 
was used to assess the discriminatory ability and validity of the model.
Results BPF and RF occurred in 259 (0.3%) and 420 patients (0.5%), respectively, in the model development dataset and in 
129 (0.3%) and 198 patients (0.5%), respectively, in the model validation dataset. Characteristic variables including types of 
surgery and comorbidities were identified as risk factors for BPF and RF, respectively. The concordance indexes of assess-
ments for BPF and RF were 0.847 (p < 0.001) and 0.848 (p < 0.001), respectively, for the development dataset and 0.850 
(p < 0.001) and 0.844 (p < 0.001), respectively, for the validation dataset.
Conclusions These models are satisfactory for predicting BPF and RF after lung cancer surgery in Japan and could guide 
preoperative assessment and optimal measures for preventing BPF and RF.
Keywords Lung cancer surgery · Broncho-pleural fistula · Respiratory failure · Risk assessment · Nationwide survey
Introduction
Lung cancer is a leading cause of death worldwide. Surgery 
remains the mainstay for complete cure. Several risk models 
and scoring systems for improving stratification of mortality 
risk associated with lung cancer surgery have been devel-
oped and tested [1–3].
Broncho-pleural fistula (BPF) and respiratory failure (RF) 
are still major devastating postoperative complications after 
pulmonary resections for primary lung cancer even though 
their incidences have decreased over the last two decades. 
Both are strongly associated with high mortality and nega-
tive impacts on activities of daily living following long-
term hospitalization. Several risk factors for BPF and RF as 
male, performance status, some comorbidities, and extensive 
resection, etc., have been suggested in patients undergoing 
pulmonary resection [4–6]. No existing risk ratio integrated 
by these risk factors responds to such medical conditions as 
development of surgical devices and less invasive surgeries 
in these days. Availability of a risk calculator at the time of 
surgery in response to a real-time medical condition would 
enable identification of surgical indications, improve surgi-
cal outcomes, maintain patient performance after surgery, 
and reduce medical costs, especially when the surgical can-
didate has multiple risk factors.
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Patients and methods
Data collection
In 2011, the NCD of Japan adopted an annual web-based 
nationwide data collection system. The Japan Surgical Soci-
ety ethics committee reviewed and approved the ethical char-
acteristics of the entire National Clinical Database initiative 
and fully disclosed the review process, on its website. The 
use of registry data for retrospective observational studies 
was approved by the committee, and the requirement of 
individual written or verbal informed consent was waived 
because of the retrospective design. In 2014, data on 1.6 mil-
lion surgical procedures from more than 4000 hospitals were 
collected [7]. An NCD specifically for general thoracic sur-
gery was launched in 2014. The data registration system and 
information recorded are described in detail in our previ-
ous report [8]. In total, 80,095 lung cancer operations were 
registered in the 2014 and 2015 datasets. More than 95% 
of all pulmonary resections for lung cancer registered with 
the Regional Bureau of Health and Welfare in Japan are 
accounted for in the NCD [9].
These databases have been audited regularly by a web-
auditing system since 2015. The audit encompasses other 
variables related to patient demographics and outcomes, 
these having been evaluated using hospitalization summa-
ries randomly selected by the NCD office since 2017. The 
high quality of the database has enabled development of risk 
models for BPF and RF after lung cancer surgery [1].
Patient cohort
The cohort for the current analysis was derived from three 
annual datasets (2014, 2015, and 2016) that included infor-
mation on persons who underwent surgical resection for pri-
mary lung cancer (at 797 surgical units in 2014, 814 in 2015, 
and 814 in 2016). Surgical approaches were categorized as 
thoracotomy or minimally invasive, including complete 
video-assisted thoracoscopic surgery and mini-thoracotomy 
with a wound length of 8 cm or less. Variables related to 
surgical approach were excluded in the risk analysis because 
decisions regarding surgical approach varied among surgi-
cal units. The surgical procedures included wedge resec-
tion, segmentectomy, lobectomy, bilobectomy, and pneu-
monectomy. Bronchoplasty (sleeve- or wedge-plasty) and 
extensive resections including chest wall, pulmonary artery, 
diaphragm, and so on were also entered into the analysis. 
Nodal dissection was categorized as hilar, lobe-specific 
mediastinal, or systematic dissection.
Patients were excluded if they had undergone proce-
dures with no curative intent, extrapleural pneumonectomy, 
complete pneumonectomy, emergency surgery, combined 
procedures for both lungs, or been transported by ambu-
lance. Of the 80,095 patients in 2014 and 2015 and the 
43,017 in 2016, 1,501 and 665 patients were excluded from 
the analysis, respectively. Thus, the development dataset for 
risk models included 78,594 patients entered in 2014 and 
2015, and the validation dataset 42,352 patients entered in 
2016.
Outcome measures
The primary outcome measures were BPF and RF occur-
ring during the index hospitalization or within 30 days after 
surgery regardless of hospitalization status. BPF was defined 
as communication between the pleural space and bronchial 
tree with/without empyema. Causes of RF after lung cancer 
surgery range from atelectasis and pneumonia to acute lung 
injury. The NCD system [8] defines RF as when a patient 
requires tracheal intubation or tracheostomy or mechani-
cal ventilation for 48 h or longer after lung cancer surgery 
regardless of cause, such as acute exacerbation of interstitial 
pneumonia, pneumonia, atelectasis, pulmonary emboli, and 
so on.
Statistical analysis
We divided the cohort into a training set (cases from 2014 to 
2015) and a validation set (cases from 2016). We constructed 
a multivariable logistic regression model that predicted the 
incidences of BPF and RF from patient demographic vari-
ables, comorbidities, and tumor conditions. Missing values 
for age and spirometry were replaced with the most frequent 
category. The estimates from the fitted models were then 
used to predict the risk for each patient in the testing cohort, 
based on the following equation: Predicted BPF (RF) = e(b0 
+ ΣbiXi)/1 + e(b0 + ΣbiXi), where bi is the coefficient of the 
variable Xi in the logistic regression equation provided in the 
tables. Xi = 1 if a categorical risk factor is present and 0 if 
it is absent. We categorized age into six levels and included 
it as a continuous variable. Xi = 0 for a patient age less than 
60, Xi = 1 for age 60–64, Xi = 2 for age 65–69, Xi = 3 for age 
70–74, Xi = 4 for age 75–79, and Xi = 5 for an age greater 
than 79. We assessed the discrimination of the model by 
examining the area under the receiver operating character-
istic curve (C-statistic) and its calibration by a calibration 
plot and the Hosmer–Lemeshow test. All analyses were 
performed with the IBM SPSS Statistics software package 
(version 24; IBM, Armonk, NY, USA).
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Results
Risk profile of study cohort
From 1 January 2014 through 31 December 2015, 78,594 
patients underwent lung cancer surgery (risk model set) and 
from 1 January 2016 through 31 December 2016, 42,352 
(validation set). The baseline characteristics of these patient 
groups were similar (Supplemental Table S1).
Outcomes
BPF and RF occurred in 259 (0.3%) and 420 patients (0.5%), 
respectively, in the model development dataset and in 129 
(0.3%) and 198 patients (0.5%), respectively, in the model 
validation dataset. The 30 day and in-hospital mortality of 
the patients who developed BPF and RF were 18.9% and 
35.7%, respectively, in the model development dataset and 
19.4% and 38.4%, respectively, in the model validation data-
set. Reoperation for the patients with BPF was performed in 
135 patients (52.1%) in the model development dataset and 
65 patients (50.4%) in the model validation dataset. Length 
of hospitalization was 35.3 ± 29.1 days in the patients with 
BPF, which is significantly longer than that of patients 
without BPF (11.3 ± 10.1 days; p < 0.001). It was 40.7 ± 28.5 
days in the patients with RF, which is significantly longer 
than that in patients without RF (11.3 ± 10.0 days; p < 0.001) 
(Supplemental Tables S2 and S3).
Model results
Multivariate risk models were developed and the final 
logistic model, with odd ratios (ORs) and 95% confidence 
intervals (CIs), is presented in Tables 1 and 2, which show 
the associations of patient baseline characteristics with the 
outcome measures of BPF and RF occurrence. 17 varia-
bles were associated with BPF occurrence and 27 with RF 
occurrence.
To evaluate model performance, the concordance-index 
(a measure of model discrimination), which is the area under 
the receiver operating characteristic curve, was used. The 
C-indices were 0.847 (95% CI 0.824–0.869; p < 0.001) for 
BPF and 0.848 (95% CI 0.831–0.865; p < 0.001) for RF. The 
C-indices in the validation datasets for BPF were 0.850 (95% 
CI, 0.819–0.881; p < 0.001) and 0.844 (95% CI 0.816–0.871; 
p < 0.001) for RF. Figure 1 shows the calibration of the mod-
els and the extent to which the rates for the predicted events 
matched those of the observed events among the patient risk 
subgroups.
Table 1  Predictors of broncho-
pleural fistula
BPF broncho-pleural fistula, CI confidence interval, FEV1 forced expiratory volume in 1  s, PS perfor-
mance status, VC vital capacity
a Clinical staging was clarified by 7th lung cancer classification
β coefficient p value Mortality model
OR (95% CI)
Sex male 1.014 < 0.001 2.756 (1.760–4.315)
BMI under 18.5 0.928 < 0.001 2.529 (1.834–3.488)
PS2 or over 0.670 0.004 1.954 (1.231–3.102)
Interstitial pneumonia 0.485 0.020 1.624 (1.079–2.446)
Central nerve system disorder 0.693 < 0.001 2.000 (1.375–2.910)
Autoimmune disease 1.026 0.001 2.789 (1.558–4.996)
Cigarette smoking habit 0.659 0.007 1.934 (1.199–3.118)
Induction radiotherapy or chemoradiotherapy 0.806 0.003 2.238 (1.309–3.826)
Clinical N1or  highera 0.498 0.002 1.645 (1.202–2.252)
Clinical stage IB or  highera 0.409 0.012 1.505 (1.096–2.068)
Surgical procedure
 Right pneumonectomy 2.460 < 0.001 11.070 (6.518–21.001)
 Right lower lobectomy 1.412 < 0.001 4.102 (3.137–5.365)
 Left pneumonectomy 0.897 0.026 2.451 (1.114–5.395)
 Bronchoplasty with segmentectomy or lobectomy 1.679 < 0.001 5.358 (3.438–8.358)
 Hilar nodal dissection or more 1.317 0.001 3.733 (1.732–8.047)
Combined resection
 Chest wall resection 0.926 0.005 2.524 (1.315–4.844)
 Wedge resection or segmentectomy of lung 0.722 0.011 2.058 (1.178–3.596)
 Intercept (β0) −9.476
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Discussion
Several risk models and scoring systems derived by analyz-
ing a big database have been developed and tested to improve 
stratification of mortality risk in lung cancer surgery [1–3]; 
however, a few studies have dealt only with BPF and/or RF 
risks [4–6]. The incidence of BPF is reportedly 0.6–4.4% 
and the mortality rate very high (18–50%), although its 
incidence has decreased over the last two decades [5]. The 
incidence of pulmonary complications ranging from atelec-
tasis to respiratory failure requiring mechanical ventilation is 
reportedly 10–20% after lung cancer surgery [10]. BPF and 
RF can both occur in the same patient. Development of BPF 
and/or RF is associated with high mortality and negative 
impacts on the patient’s daily life despite lengthy hospitali-
zation and large medical costs.
Various risk factors ranging from patient’s characteristics 
to operative procedures have been reported to be associated 
with the development of BPF or RF. Few studies, however, 
have used multivariate analysis to assess integrated risk cal-
culation of various factors on large clinical databases. Most 
previous studies had small patient cohorts, few BPF or RF 
events, and biased patient selection and surgical procedures, 
among other limitations.
Risk assessments for mortality and/or major morbidities 
after pulmonary resection for primary lung cancer using 
Table 2  Predictors of 
respiratory failure
CI confidence interval, FEV1 forced expiratory volume in 1 s, RF respiratory failure; VC: vital capacity
a The variable of age was categorized into six groups, namely less than 60, 60 to 64, 65 to 69, 70 to 74, 75 
to 79, and more than 80 years old. Therefore, this odds ratio indicates an alteration of relative risk per one 
unit increase in age category
b Clinical staging was clarified by 7th lung cancer classification
β coefficient p value Mortality model
OR (95% CI)
Sex male 0.476 0.004 1.595 (1.163–2.188)
Age  categorya 0.219 < 0.001 1.245 (1.156–1.341)
BMI under 18.5 0.738 < 0.001 2.091 (1.613–2.710)
BMI over 30 0.682 0.008 1.978 (1.198–3.265)
Performance status 1 0.629 < 0.001 1.875 (1.499–2.345)
Performance status 2 or higher 0.724 < 0.001 2.063 (1.452–2.930)
% VC 10% decrease (100–50%) 0.308 < 0.001 1.361 (1.273–1.455)
FEV1% 10% decrease (100–50%) 0.550 < 0.001 1.734 (1.343–2.239)
Liver cirrhosis (Child–Pugh B/C) 1.323 < 0.001 3.756 (1.807–7.808)
Interstitial pneumonia 1.107 < 0.001 3.024 (2.312–3.956)
Coronary artery disease 0.422 0.006 1.524 (1.127–2.062)
Central nerve system disorder 0.575 < 0.001 1.776(1.342–2.352)
Arrhythmia 0.610 0.001 1.840 (1.301–2.603)
Cigarette smoking 30 pack-years or more 0.462 0.001 1.587 (1.214–2.074)
Tumor size > 3 cm 0.343 0.005 1.410 (1.108–1.793)
Clinical T1b or  higherb 0.299 0.025 1.349 (1.038–1.753)
Clinical T3 or  higherb 0.350 0.033 1.419 (1.028–1.980)
Clinical stage III or  higherb 0.386 0.011 1.471 (1.092–1.958)
Histology squamous cell carcinoma 0.369 0.001 1.447 (1.166–1.795)
Superior sulcus tumor 0.516 0.022 1.675 (1.079–2.601)
Multiple lung cancers 0.984 < 0.001 2.675 (1.722–4.157)
Surgical procedure
 Right pneumonectomy 1.538 < 0.001 4.655 (2.507–8.642)
 Right upper lobectomy 0.350 0.002 1.418 (1.135–1.772)
 Bilobectomy 1.425 < 0.001 4.159 (2.223–7.282)
 Bronchoplasty with segmentectomy or lobectomy 0.651 0.009 1.917 (1.174–3.131)
 Hilar nodal dissection or more 0.813 < 0.001 2.254 (1.591–3.193)
Combined resection
 Chest wall resection (other than first rib) 0.857 0.001 2.356 (1.447–3.835)
 Chest wall resection (first rib) 1.257 0.004 3.515 (1.492–8.282)
 Intercept (β0) −9.741
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approximately 80,000 surgery data from NCD were devel-
oped in the previous paper [1]. In this study, we additionally 
developed a model for estimating risk of BPF and RF using 
approximately 120,000 data derived from NCD for surgi-
cal decision-making and perioperative care. The NCD for 
lung cancer surgery provides a large number of lung cancer 
patients annually (approximately 40,000) who have under-
gone pulmonary resection, allowing identification of some 
variables as independent predictors of BPF and RF. Further-
more, these factors were validated using datasets obtained 
in 2016.
When surgeons input preoperative data and the planned 
surgery type, a BPF and RF risk models can improve pre-
operative assessment, including determination of surgical 
indications and the suitability of limited resection. It can 
also recommend individualized perioperative management 
as perioperative treatment or rehabilitation.
Risk factors for BPF
Male sex has consistently been identified as a risk factor 
in other models of lung cancer surgery risk [11]. Being 
underweight may be linked to sarcopenia, immune–nutri-
tional deficiencies, and wound healing problems [12]. The 
American Society of Anesthesiologists physical status, 
which is estimated by number of comorbidities and their 
severity, may be a more useful indicator than performance 
status of development of pulmonary complications in older 
patients being considered for thoracoscopic lobectomy 
[13]. The NCD system requires entry of all comorbidities, 
thus enabling our identification of interstitial pneumonia, 
stroke, and autoimmune disease as comorbidities signifi-
cantly associated with risk of BPF. Interstitial pneumonia is 
a known major risk factor for operative mortality after lung 
cancer surgery [1]. Acute exacerbation of interstitial pneu-
monia causing respiratory failure and requiring mechani-
cal ventilation may be linked to development of BPF [14]. 
Autoimmune disease is possibly linked to immunosuppres-
sive treatments such as steroids and/or potential delays in 
wound healing. Whether such immunosuppressive treat-
ments should be continued should be carefully discussed 
with physicians [15].
Several studies have concluded that diabetes melli-
tus (DM) is a risk factor for BPF [16]; however, we did 
not confirm this in our study. DM status is categorized in 
the NCD system as follows: untreated, dietary treatment 
only, non–insulin treatment, and insulin-dependent. There 
are few patients with untreated DM in our series because 
we excluded patients requiring emergency surgery. Most 
patients’ DM is now successfully controlled before surgery, 
even if they have severe DM. The presence of uncontrolled 
DM may be a risk factor for BPF. Neoadjuvant therapy is 
considered a major risk factor [17]. There has recently been 
an increased focus on radiation intervention in relation to 
BPF in studies of neoadjuvant therapy prior to surgery.
Pneumonectomy, especially right sided, is a known high-
risk surgical procedure for BPF. Furthermore, right lower 
lobectomy has also been identified as a risk factor for BPF 
[18]. After both of these procedures the bronchial stump 
may be bare to the pleural cavity with minimal covering by 
mediastinal tissue or residual lung [5, 19]. Nodal dissec-
tion may strip the bronchial circulation, resulting in bron-
chial ischemia. Chest wall resection may adversely affect 
Fig. 1  Calibration of the broncho-pleural fistula (BPF) (a) and respir-
atory failure (RF) (b) models
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postoperative ventilation and bronchial circulation by strip-
ping intercostal arteries.
Prevention of BPF
Bronchial stump coverage is the most frequently performed 
preventive procedure against BPF in high-risk patients; how-
ever, no randomized control studies have been conducted to 
clarify its efficacy as a preventive procedure against BPF. 
Some studies have reported that bronchial stump coverage 
is ineffective. In a prospective study of pneumonectomy in 
patients with DM, intercostal muscle flap coverage in high-
risk patients was reported to confer significant benefit: no 
BPF occurred in the reinforcement arm [20]. Another study 
has reported a slightly higher incidence of BPF in high-risk 
patients who underwent bronchial stump coverage than in 
low-risk patients who did not [21]. Despite the lack of con-
clusive evidence, most thoracic surgeons believe that bron-
chial stump coverage can prevent from BPF. The extent of 
nodal dissection should also be considered.
Reoperation was saved in half of the patients with BPF. 
The result suggested that postoperative care of patients at 
high-risk of BPF must include close monitoring and urgent 
intervention to avoid surgical intervention for BPF [22].
Risk factors for RF
RF occurs due to pulmonary complications ranging from 
atelectasis and pneumonia to acute lung injury. Not only 
sarcopenia but obesity has been identified as a risk factor 
for RF. The spirometric variables of percent vital capac-
ity (%VC) and forced expiratory volume 1.0% (FEV1.0%) 
are major risk factors for RF. Low %VC and FEV1.0% are 
risk indicators in patients with restrictive lung disease and 
chronic obstructive pulmonary disease (COPD), respec-
tively. Recent studies have suggested the diffusion capacity 
of the lung for carbon monoxide (DLCO) is a more reliable 
predictor of RF in patients with restrictive lung disease [23]. 
The NCD system did not require data entry for DLCO until 
NCD 2016, because the DLCO test was infrequently per-
formed in Japanese surgical units. Considering interstitial 
pneumonia is one of the risk factors for RF, DLCO will 
likely become a significant risk factor for RF in the near 
future, because it has been possible to enter DLCO since 
NCD 2017.
Organ failure such as hepatic dysfunction, ischemic heart 
disease, and central nerve disorder is also a risk factor for 
RF. Hepatic cirrhosis is a key prognostic factor in patients 
with acute respiratory distress syndrome [24].
Multiple lung cancers, which have increasingly been diag-
nosed since development of high-resolution chest computed 
tomography in this decade, are a risk factor for RF. Volume 
of resected lung may contribute to the RF risk likely in the 
patients undergoing right pneumonectomy or bilobectomy.
Few studies have investigated risk calculation of RF after 
pulmonary resection [6]. Risk of pulmonary complications 
is reportedly associated with administration of induction 
chemotherapy and predicted postoperative DLCO. Despite 
its simplicity, that model was found to be poor by external 
validation [25]. The model we developed from the 2014 and 
2015 NCD datasets is surprisingly satisfactory according to 
the model validation dataset of NCD 2016 because we ana-
lyzed a dataset of approximately 80,000 lung cancer surger-
ies and the spectrum of RF was limited based on definition 
as a complication of atelectasis and pneumonia requiring 
tracheal intubation or tracheostomy or mechanical ventila-
tion for 48 h or longer after lung cancer surgery regardless 
of complications such as acute exacerbation of interstitial 
pneumonia, pneumonia, atelectasis, pulmonary emboli, and 
so on [8].
Prevention of RF
Prediction of postoperative complications and long-term dis-
ability caused by pulmonary resection requires preoperative 
physiologic rehabilitation or treatment, to reduce a risk of 
respiratory failure for lung cancer patients with underlying 
pulmonary diseases such as idiopathic pulmonary fibrosis 
(IPF) [26] or chronic obstructive disease [27]. Planned surgi-
cal invasiveness as indicated by surgical approach, volume 
of resected lung, extent of nodal dissection, and extensive 
resection can have major physiological impacts on postop-
erative respiratory function in these patients. Less invasive 
approach as video-assisted thoracoscopic surgery or robotic 
surgery should be considered when risk calculation suggests 
high-risk [28, 29]. Palliative sublobar resection should be 
considered if applicable. Nodal dissection increases tissue 
damage by reducing lymphatic drainage and denervating the 
vagal nerve, thus increasing the pulmonary complication 
rate after lung cancer surgery [30]. Nodal sampling should 
be indicated by preoperative PET assessment or waived by 
nodal assessment through transbronchial lymph node biopsy.
Basic perioperative care including oxygen therapy, fluid 
management, use of bronchodilator and anti-IPF agent, and 
rehabilitation, etc., should be careful [31].
Study limitations
Our attempt to develop an ideal model for predicting risk 
of BPF and RF after lung cancer surgery has the following 
limitations.
1. The risk model was developed using a large amount of 
data from the NCD specifically concerning general tho-
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racic surgery in Japan. The NCD includes mostly a sin-
gle race (Japanese), and contains few patients with high 
BMI, peripheral vascular disease, or untreated DM. The 
characteristics of enrolled patients may, therefore, differ 
from those of previous studies. Variations in risk models 
that are related to regional differences in data collection 
are of concern. In the future, we plan to develop a com-
patible risk calculator for other countries by streamlin-
ing the version for both models.
2. BPF may have been misdiagnosed and entered as pro-
longed pulmonary air leakage when the BPF was small. 
BPF is subject to entry error and under-reporting and 
this would have affected the model.
3. BPF and RF can develop over 30 days after surgery 
[32]. Late complications over 30 days after surgery are 
not entered into the NCD data entry system. Therefore, 
some patients with late onset of these complications may 
have been under-reported.
4. The NCD does not include fluid intake during surgery, 
which may be linked to RF, or operative procedures such 
as closure technique (manual or stapled), or bronchial 
covering, which may be associated with occurrence of 
BPF. These issues should be considered in future stud-
ies.
Updated risk model
Our analysis provided a risk model for BPF or RF after 
lung cancer surgeries based on the NCD 2014 and 2015 
dataset. Validation analysis using the NCD 2016 data-
set confirmed the feasibility of the risk model. However, 
patient characteristics, lung cancer oncology, treatment 
strategies, and development of surgical devices will con-
tinue to change as population age and medical science 
advances. Risk models for BPF and RF will, therefore, 
need to be reviewed, particularly in rapidly changing 
societies. Our annual data collection system of NCD will 
respond to these changes and enable updating of risk mod-
els for BPF and RF after lung cancer surgery [8].
In summary, models estimating risk of BPF and RF 
after lung cancer surgery based on the 2014 and 2015 
NCD datasets precisely predicted occurrence of BPF and 
RF after lung cancer surgeries according to the 2016 NCD 
dataset. The model can facilitate perioperative assessment 
and planning of operative procedures to prevent BPF and 
RF.
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